| Overview |
| bsm-0990M-Cy7 |
| HPV16 E6 protein (2E3) Monoclonal Antibody, Cy7 Conjugated |
| IF(IHC-P) |
| Virus |
| Specifications |
| Cy7 |
| Mouse |
| KLH conjugated synthetic peptide derived from HPV16 E6 protein |
| 85-158/158 |
| Monoclonal |
| 2E3 |
| IgG |
| 1ug/ul |
| Purified by Protein G. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1489078 |
| P03126 |
| Protein E6; E6 |
| Plays a major role in the induction and maintenance of cellular transformation. Acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. E6 associates with host E6-AP ubiquitin-protein ligase, and inactivates tumor suppressors TP53 and TP73 by targeting them to the 26S proteasome for degradation. In turn, DNA damage and chromosomal instabilities increase and lead to cell proliferation and cancer development. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX1-91, a repressor of human telomerase reverse transcriptase (hTERT). The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization. Other cellular targets including Bak, Fas-associated death domain-containing protein (FADD) and procaspase 8, are degraded by E6/E6AP causing inhibition of apoptosis. E6 also inhibits immune response by interacting with host IRF3 and TYK2. These interactions prevent IRF3 transcriptional activities and inhibit TYK2-mediated JAK-STAT activation by interferon alpha resulting in inhibition of the interferon signaling pathway. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz